Page last updated: 2024-09-04

rp 73401 and Granulocytic Leukemia

rp 73401 has been researched along with Granulocytic Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barzago, MM; Cecconi, V; Garattini, E; Gianni', M; Nigro, E; Parrella, E; Rambaldi, A; Rochette-Egly, C; Terao, M	1

Other Studies

1 other study(ies) available for rp 73401 and Granulocytic Leukemia

Article	Year
Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. The Journal of biological chemistry, 2004, Oct-01, Volume: 279, Issue:40 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasm Transplantation; Pyridines; Retinoids; Second Messenger Systems; Transcription Factors; Transplantation, Heterologous; Treatment Outcome; Tretinoin; Tumor Cells, Cultured	2004

Article

Year

Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.

The Journal of biological chemistry, 2004, Oct-01, Volume: 279, Issue:40

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasm Transplantation; Pyridines; Retinoids; Second Messenger Systems; Transcription Factors; Transplantation, Heterologous; Treatment Outcome; Tretinoin; Tumor Cells, Cultured

2004